Avilar Therapeutics to Present Preclinical Data on Preeclampsia Treatment at International Symposium
Avilar Therapeutics, a biopharmaceutical company specializing in extracellular protein degraders, is set to showcase preclinical data for its sFlt1 ATAC (ASGPR Targeting Chimera) program. This program is focused on developing a treatment for preeclampsia, a severe pregnancy complication. The data will be presented in a poster at the 2nd Hamburg International Symposium on Maternal-Fetal Medicine, scheduled for October 9-10, 2026, in Hamburg, Germany. This marks the first time the program's findings will be disclosed at a scientific meeting dedicated to maternal-fetal medicine. Preeclampsia affects up to 8% of pregnancies globally, and currently, the only definitive treatment involves delivering the baby, often prematurely. Elevated levels of circulating sFlt1, produced by the placenta, are a primary cause of the disease's characteristic blood vessel dysfunction and organ damage. Avilar's sFlt1 ATAC is designed to bind to sFlt1 in the maternal circulation and direct it to the liver for degradation via the bo...
